P-Cure, an Israeli company specializing in proton therapy, has commenced construction on a proton therapy center in Taian city, Shandong province, China, according to a report by the South China Morning Post. The development is being carried out by P-Cure’s Chinese subsidiary, SIHA, with the goal of providing precision cancer treatment at a cost of approximately USD 28,200, which is about 50% less than current proton therapy services available in China.
Yang Chen, chairman of SIHA, is quoted in the report, stating that P-Cure plans to establish additional centers in hospitals across the country, capitalizing on the low cost of its ultra-compact, 360-degree, gantry-less adaptive proton therapy system. This system is significantly more affordable than the market alternatives, which typically cost around USD 50 million, and can be constructed in approximately 2 years, compared to the 5 years required by competitors. P-Cure’s proton therapy platform includes diagnostic-quality 4D computed tomography (CT) scanning, pencil beam scanning, a robotic positioning system, constant radioscopic and fluoroscopic imaging, and positioning software for precise tumor targeting. The platform is capable of treating various types of cancer, including those of the lung, breast, chest, head and neck, and lower torso.- Flcube.com
